- After submitting a written response to the FDA's request for additional information on Meridian Bioscience Inc's (NASDAQ: VIVO) Revogene SARS-CoV-2 test on February 16 and further discussions with the FDA, the company decided to withdraw its Emergency Use Authorization (EUA) application.
- The company plans to conduct a new clinical validation study and a Limit-of-Detection bridging study, with potential re-submission of a EUA application during Q3 of 2021.
- Price Action: VIVO is down 3.39% at $22.23 on the last check Tuesday.
Meridian Bioscience Pulls Out Revogene COVID-19 Test EUA Application
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.